|

Keytruda Clinical Trials

8 actively recruiting trials across 3 locations

No change since May 2026

Also known as: MK-3475, Pembrolizumab, pembrolizumab

Pipeline

Phase 2: 4Phase 3: 1Phase 1/2: 3

Top Sponsors

  • University of Leipzig1
  • Strand Therapeutics Inc.1
  • Qilu Pharmaceutical Co., Ltd.1
  • Philogen S.p.A.1
  • National Cancer Institute (NCI)1

Indications

Other5 trials

A Study to Evaluate Efficacy, and Safety of QL2107 Plus Chemo and Compare With Keytruda in Participants With IV nqNSCLC
Phase 3
European Larynx Organ Preservation Study (ELOS) [MK-3475-C44]
Phase 2
IBI363 Combined With Chemotherapy or Pembrolizumab Combined With Chemotherapy as Neoadjuvant Therapy in Resectable Stage IB-III Non-Squamous Non-Small Cell Lung Cancer
Phase 2
OH2 Injection in Solid Tumors
Phase 1/2
Preoperative Immunotherapy Combined With Stereotactic Radiation Therapy Boost in the Treatment of HER2-negative Breast Cancer
Phase 2

Scottsdale, Arizona1 trial

Phase 1/2 Study of Intratumoral Injection of STX-001 in Advanced Solid Tumors as Monotherapy or in Combination With Pembrolizumab

HonorHealth Research and Innovation Institute

Phase 1/2

Bethesda, Maryland1 trial

A Study of CDX-1140, a CD40 Agonist, in Combination With Capecitabine and Oxaliplatin (CAPOX) and Keytruda in Subjects With Biliary Tract Carcinoma (BTC)

National Institutes of Health Clinical Center

Phase 1/2

New York, New York1 trial

Study of the Efficacy of Intratumoral L19IL2 or L19TNF or L19IL2/L19TNF, in Combination with Pembrolizumab, in Unresectable Melanoma Patients

Memorial Sloan Kettering Cancer Center

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.